Celcuity Inc. Reports Quarterly Loss Exceeding Expectations

Celcuity Inc., a clinical-stage biotechnology company based in Minneapolis, United States, has recently reported a quarterly loss that surpassed market expectations. The company, which specializes in developing targeted therapies for multiple solid tumor indications, saw its stock price decline following the announcement. This news was reported by de.investing.com on August 14, 2025, at 20:34 UTC.

Celcuity’s financial performance for the quarter was highlighted by a non-GAAP earnings per share (EPS) of -$0.93, which missed the anticipated figure by $0.09, as reported by Seeking Alpha on the same day at 20:12 UTC. This shortfall in earnings has contributed to the negative sentiment surrounding the company’s stock.

As of August 12, 2025, Celcuity’s stock was trading at a close price of $52.37, with a 52-week high of $53.40 and a low of $7.575 recorded on April 7, 2025. The company’s market capitalization stands at approximately $2.45 billion USD.

Insights into Upcoming Earnings

Prior to the release of the quarterly results, Benzinga provided insights into Celcuity’s upcoming earnings on August 13, 2025. The anticipation surrounding the earnings report was significant, given the company’s focus on innovative therapies within the health care sector.

Celcuity Inc., listed on the Nasdaq stock exchange, continues to serve clients primarily in the United States. Since its Initial Public Offering (IPO) on September 20, 2017, the company has been actively involved in the biotechnology industry, aiming to advance treatments for various solid tumor indications.

For more information, stakeholders and interested parties can visit Celcuity’s official website at www.celcuity.com .